A
Overall survival
You're currently viewing OncGenius as a guest. To save your results, create an account or log in.
Advertisement
At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Slamon et al presented results from the phase III NATALEE trial, which evaluated adjuvant ribociclib plus endocrine therapy in a broad population of patients with early breast cancer who were at risk for recurrence (Abstract LBA500).